| CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9). CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is also progressing several gene-edited allogeneic cell therapy programs. Co.'s product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia and severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. We show 13 historical shares outstanding datapoints in our CRSP shares outstanding history coverage, used to compute CRSP market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CRSP market cap history over the course of time is important for investors
interested in comparing CRSP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CRSP versus a peer is one thing; comparing
CRSP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CRSP can fluctuate over the course of history.
With this page we aim to empower investors researching CRSP by allowing them to research the CRSP market cap history.